Authors
Xiaoning Sun, Jamie J Kwan, Krishna Kothari, Alexandra F Nazzari, Astrid Kosters, Colin A Fields, Bao Q Thai, Deepta Bhattacharya, Michael Atkins, Kelvin W Chan Tung, Xinyuan Zhao, Ameena Romani, Brock McKinney, Peter J Cook, David J Rawlings, Richard G James, Vladimir T Manchev, Marion Kennedy, Eliver E B Ghosn, Gordon M Keller
Published in
Cell stem cell. Nov 19, 2026. Epub Nov 19, 2026.
Abstract
The ability to generate functional B cells from human pluripotent stem cells (hPSCs) would open new opportunities to develop novel B cell-based therapies. Here, we established a protocol that promotes the development of B lineage cells from hPSC-derived hematopoietic progenitors. hPSC-derived B cell development transitions through pro-B, pre-B, and naive B cell stages, accurately recapitulating B lymphopoiesis. These naive B cells mature into antibody-secreting plasma cells that undergo class switching in vitro and engraft immunodeficient mice and produce immunoglobulin G (IgG) in vivo. Analyses of signaling pathways that regulate B lymphopoiesis uncovered a potent inhibitory effect of interleukin (IL)-7 on functional immunoglobulin heavy-chain (IgH) rearrangement. Both definitive and yolk sac progenitors were found to display B cell potential, revealing distinct developmental sources of human B lineage cells. Together, these findings provide a system for investigating the earliest stages of human B lymphopoiesis and a source of appropriately staged plasma cells for future therapeutic applications.
PMID:
43057234
Bibliographic data and abstract were imported from PubMed on 20 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 4
- Comments 0